InvestSMART

Cyclopharm Limited (ASX:CYC)

ALERT: Price-sensitive ASX Announcement for CYC
Current share price for CYC : $0.525 -0.225 (-30%)+
Announcement
Release
24 Mar 2026 8:28AM
Price at Release
$0.750
Full Release
download
Summary
Cyclopharm Limited, an ASX-listed radiopharmaceutical company, announced a multi-site agreement with Northwestern Medicine, a leading academic health system based in Chicago, Illinois. The agreement includes one immediate installation of the Technegas® technology at Northwestern Memorial Hospital and the potential for up to six additional installations across the Northwestern Medicine network. This strategic move aims to establish a significant presence in the Chicago healthcare market, which is among the largest in the US, and supports Cyclopharm’s US expansion strategy. The agreement is part of Cyclopharm's efforts to secure high-quality reference sites within leading US academic health systems, thereby expanding its footprint across integrated delivery networks. Cyclopharm’s Managing Director and CEO, James McBrayer, highlighted the importance of this agreement as a milestone in their US expansion strategy.
Key Points
  • Multi-site agreement with Northwestern Medicine in Chicago.
  • Immediate installation of Technegas® at Northwestern Memorial Hospital.
  • Potential for up to six additional installations across the network.
  • Strategic entry into the Chicago healthcare market.
  • Part of Cyclopharm's US expansion strategy.
  • Focus on establishing high-quality reference sites.
  • Cyclopharm’s growing adoption in major US healthcare systems.
  • James McBrayer comments on the strategic milestone.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.